SCHEMBL29914938

SCHEMBL29914938

CCOc1cc(Br)cc2c1C(=O)OC2

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
GAA P10253 1/20 0.41
MAOA P21397 3/20 0.40
MAOB P27338 3/20 0.40
HTT P42858 3/20 0.40
KMT2A Q03164 1/20 0.40
LMNA P02545 4/20 0.39
KCNJ1 P48048 1/20 0.38
KCNH2 Q12809 1/20 0.38
CYP3A4 P08684 1/20 0.38
RECQL P46063 1/20 0.38
IGF1R P08069 1/20 0.37
PDE5A O76074 1/20 0.36
PDE4A P27815 1/20 0.36
PDE1A P54750 1/20 0.36
PDE1B Q01064 1/20 0.36
PDE4B Q07343 1/20 0.36
PDE4C Q08493 1/20 0.36
PDE4D Q08499 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27002518 1.00 KDM4E (0.41) KDM4ESMN1; SMN2GAAMAOAMAOB
SCHEMBL31496832 0.82 CYP3A4 (0.53) KDM4ESMN1; SMN2GAAMAOAMAOB
SCHEMBL31496867 0.79 MAOA (0.36) KDM4ESMN1; SMN2GAAMAOAMAOB
SCHEMBL31496825 0.79 MAOA (0.36) KDM4ESMN1; SMN2GAAMAOAMAOB
SCHEMBL31496882 0.78 MAOA (0.39) KDM4ESMN1; SMN2GAAMAOAMAOB
SCHEMBL31496906 0.75 KDM4E (0.38) KDM4ESMN1; SMN2GAAMAOAMAOB
SCHEMBL2221729 0.75 KDM4E (0.42) KDM4ESMN1; SMN2GAAMAOAMAOB
SCHEMBL25256864 0.73 KDM4E (0.40) KDM4ESMN1; SMN2GAAMAOAMAOB
SCHEMBL30833179 0.73 KDM4E (0.40) KDM4ESMN1; SMN2GAAMAOAMAOB
SCHEMBL23723787 0.73 KDM4E (0.37) KDM4ESMN1; SMN2GAAMAOAMAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240208912-A1 MTA-Cooperative PRMT5 Inhibitors MIRATI THERAPEUTICS INC (US) 2024-06-27 US disclosed
EP-4304720-A1 MTA-COOPERATIVE PRMT5 INHIBITORS Mirati Therapeutics, Inc. (US) 2024-01-17 EP disclosed
WO-2022192745-A1 MTA-COOPERATIVE PRMT5 INHIBITORS Mirati Therapeutics, Inc. (US) 2022-09-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240208912-A1 MTA-Cooperative PRMT5 Inhibitors PRMT1, PRMT5, PRMT6 KDM4E 644/4885SMN1; SMN2 2715/4885GAA 3637/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.